mCSPC
Advertisement
Dr. Greenstein shares insights on the overall survival benefit of apalutamide over enzalutamide in a recent real-world study.
Dr. Armstrong reviews a handful of GU studies presented, including NIAGRA and STAMPEDE.
Drs. Tawagi and Wallis review the PEACE-III, STAMPEDE, UpFrontPSMA, and SPLASH studies trials at the ESMO Congress 2024.
The panel concludes with thoughts on the evolving landscape of PC treatment, focusing on multidisciplinary collaboration.
Future Directions in Metastatic PC: Exploring Monotherapy, Novel Therapies, and Strategic Sequencing
The panel ponders the future of metastatic prostate cancer treatment, emphasizing the potential of emerging therapies.
The panel considers the decision-making process for chemo eligibility in mHSPC, emphasizing the role of patient education.
Implementing Triplet Therapy for mHSPC: Collaboration, Patient Communication, and QOL Considerations
The panel delves into triplet therapy for mHSPC, highlighting the benefits and logistics of the ARASENS regimen.
The panel shares insights on managing mHSPC, emphasizing patient communication and evolving role of novel therapies.
The panel explores the challenges involved in managing mHSPC, focusing on difficulties with obtaining PSMA scans.
Dr. Pobel offers an overview of the ancillary study of the PEACE-1 trial, including how immunohistochemistry was used.
Prognostic and predictive phenotypic biomarkers have been identified for rPFS and OS in de novo mCSPC.
Dr. Gebrael discusses the impact of baseline bone pain on survival outcomes in mHSPC.
There is a lack of research investigating associations between bone pain and OS in patients with mHSPC.
Darolutamide plus ADT provided a clinically meaningful increase in rPFS compared with placebo plus ADT.
Dr. Lowentritt sheds light on a real-world comparison of PSA response in patients with mCSPC treated with apalutamide.
Intensified androgen blockade improves PSA progression-free survival in prostate cancer without affecting quality of life.
The ArteraAI MMAI prognostic biomarker performs risk stratification of patients with localized prostate cancer.
Researchers evaluated differences in treatment intensification and overall survival between patient groups.
An analysis of the phase 3 ARASENS study revealed new information on PSA responses and their association with outcomes.
Researchers performed a post hoc analysis on patient data from the randomized, phase 3 LATITUDE trial.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.